Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review

Date: June 21, 2016
Pages: 49
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: VA8DE3593DFEN
Leaflet:

Download PDF Leaflet

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review
Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Veloxis Pharmaceuticals A/S (Veloxis) is a specialty pharmaceutical company, which develops therapies for kidney transplantation based on its proprietary MeltDose platform. MeltDose is a drug delivery technology, used to enhance oral bioavailability and control release of a drug. The company’s product portfolio consists of Envarsus XR and Fenoglide. It markets and sells Envarsus XR anti-rejection drug, tacrolimus for patients who had kidney transplantation in the US, Europe, Turkey and CIS Countries. The company has a wholly owned subsidiary, Veloxis Pharmaceuticals Inc., in New Jersey, the US. Veloxis is headquartered in Horsholm, Denmark.

Veloxis Pharmaceuticals AS Key Recent Developments

May 18, 2016: Veloxis Pharmaceuticals announces financial results for the first three months of 2016
Apr 06, 2016: Veloxis announces change in management
Mar 09, 2016: Veloxis Pharmaceuticals moves Danish activates to the U.S
Mar 09, 2016: Veloxis Pharmaceuticals publishes Annual Report 2015
Feb 29, 2016: Veloxis appoints Alastair McEwan as new Chief Operating Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Veloxis Pharmaceuticals A/S - Key Facts
Veloxis Pharmaceuticals A/S - Key Employees
Veloxis Pharmaceuticals A/S - Key Employee Biographies
Veloxis Pharmaceuticals A/S - Major Products and Services
Veloxis Pharmaceuticals A/S - History
Veloxis Pharmaceuticals A/S - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Veloxis Pharmaceuticals A/S - Business Description
Veloxis Pharmaceuticals A/S - Corporate Strategy
Veloxis Pharmaceuticals A/S - SWOT Analysis
SWOT Analysis - Overview
Veloxis Pharmaceuticals A/S - Strengths
Strength - Focused Research and Development Activities
Strength - Proprietary Technology Platforms
Strength - Lead Product – Envarsus
Veloxis Pharmaceuticals A/S - Weaknesses
Weakness - Declining Profitability
Veloxis Pharmaceuticals A/S - Opportunities
Opportunity - Changing Demographics
Opportunity - Rising Healthcare Expenditure in the US
Opportunity - Orphan Drug Designation: Envarsus
Veloxis Pharmaceuticals A/S - Threats
Threat - Uncertain R&D Outcomes
Threat - Stringent Government Regulations
Threat - Intense Competition
Veloxis Pharmaceuticals A/S - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Veloxis Pharmaceuticals A/S, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 18, 2016: Veloxis Pharmaceuticals announces financial results for the first three months of 2016
Apr 06, 2016: Veloxis announces change in management
Mar 09, 2016: Veloxis Pharmaceuticals publishes Annual Report 2015
Feb 29, 2016: Veloxis appoints Alastair McEwan as new Chief Operating Officer
Dec 10, 2015: Veloxis announces change in management
Nov 11, 2015: Veloxis Pharmaceuticals announces financial results for the first nine months of 2015
Aug 26, 2015: Veloxis Pharmaceuticals announces financial results for the first six months of 2015 and improves the full year outlook
May 20, 2015: Veloxis Pharmaceuticals announces financial results for the first three months of 2015
Mar 03, 2015: Veloxis Pharmaceuticals publishes Annual Report 2014

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Veloxis Pharmaceuticals A/S, Key Facts
Veloxis Pharmaceuticals A/S, Key Employees
Veloxis Pharmaceuticals A/S, Key Employee Biographies
Veloxis Pharmaceuticals A/S, History
Veloxis Pharmaceuticals A/S, Subsidiaries
Veloxis Pharmaceuticals A/S, Key Competitors
Veloxis Pharmaceuticals A/S, Ratios based on current share price
Veloxis Pharmaceuticals A/S, Annual Ratios
Veloxis Pharmaceuticals A/S, Interim Ratios
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Veloxis Pharmaceuticals A/S, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Veloxis Pharmaceuticals A/S, Performance Chart (2011 - 2015)
Veloxis Pharmaceuticals A/S, Ratio Charts
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Veloxis Pharmaceuticals A/S, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016

COMPANIES MENTIONED

Quantum Genomics SA
NeuroSearch A/S
H. Lundbeck A/S
ALK-Abello A/S
Affitech A/S
Skip to top


Ask Your Question

Veloxis Pharmaceuticals AS (VELO) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: